GSK - Why iTeos Therapeutics Stock Soared Today
Shares of iTeos Therapeutics (NASDAQ: ITOS) surged 37% on Monday after it reached an agreement with GlaxoSmithKline (NYSE: GSK) to co-develop an experimental cancer treatment known as EOS-448.
EOS-448 is a monoclonal antibody treatment for patients with cancer. It's currently being evaluated in a phase 1 study in patients with advanced solid tumors. GlaxoSmithKline also intends to begin new combination studies of EOS-448 with some of its other immuno-oncology therapies next year.
iTeos Therapeutics and GlaxoSmithKline struck a major new development deal. Image source: Getty Images.
For further details see:
Why iTeos Therapeutics Stock Soared Today